Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00013585 · ClinicalTrials.gov registry record · Phase 2
Safety and Effectiveness of the Selegiline "Patch" for Decreased Mental Function in HIV Patients
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 127
- Enrollment target
NCT00013585 is a Phase 2 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 127 participants.
The verdict
NCT00013585, a Phase 2 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 127 participants
- Enrollment target
Study Summary
A decrease in mental function often occurs in patients with HIV. Antiretroviral (ARV) drugs are used to treat this but are not entirely effective. Some other therapy could play a role. The drug selegiline in its pill form is used to treat Parkinson's disease, a serious brain disorder. It is believed this drug might protect the brain and repair some damage. This study will use this drug in a "patch" form, which has not been approved by the Food and Drug Administration (FDA), to see if it helps with decreased mental function in patients with HIV. The purpose of this study is to evaluate the use of selegiline transdermal system (STS) in the treatment of decreased mental function in patients with HIV.
Interventions
- DRUG Selegiline hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 127 participants |
| Est. Completion | 2005-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00013585
The ClinicalTrials.gov registry entry for NCT00013585 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 127 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Selegiline hydrochloride is the first listed.
NCT00013585 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00013585 about?
NCT00013585 is a clinical study titled "Safety and Effectiveness of the Selegiline "Patch" for Decreased Mental Function in HIV Patients". A decrease in mental function often occurs in patients with HIV. Antiretroviral (ARV) drugs are used to treat this but are not entirely effective. Some other therapy could play a role. The drug selegiline in its pill form is used to treat Parkinson's disease, a serious brain disorder. It is believed...
What is the current status of trial NCT00013585?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 127 participants. Estimated completion is 2005-12.
What interventions are being tested in trial NCT00013585?
The interventions under investigation include: Selegiline hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00013585?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.